263 related articles for article (PubMed ID: 27322959)
1. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
2. Iron Binding and Iron Removal Efficiency of Desferrioxamine Based Polymeric Iron Chelators: Influence of Molecular Size and Chelator Density.
Hamilton JL; Ul-Haq MI; Creagh AL; Haynes CA; Kizhakkedathu JN
Macromol Biosci; 2017 Mar; 17(3):. PubMed ID: 27683190
[TBL] [Abstract][Full Text] [Related]
3. Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo.
Imran ul-haq M; Hamilton JL; Lai BF; Shenoi RA; Horte S; Constantinescu I; Leitch HA; Kizhakkedathu JN
ACS Nano; 2013 Dec; 7(12):10704-16. PubMed ID: 24256569
[TBL] [Abstract][Full Text] [Related]
4. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
[TBL] [Abstract][Full Text] [Related]
6. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators.
Rossi NA; Mustafa I; Jackson JK; Burt HM; Horte SA; Scott MD; Kizhakkedathu JN
Biomaterials; 2009 Feb; 30(4):638-48. PubMed ID: 18977029
[TBL] [Abstract][Full Text] [Related]
7. First human studies with a high-molecular-weight iron chelator.
Dragsten PR; Hallaway PE; Hanson GJ; Berger AE; Bernard B; Hedlund BE
J Lab Clin Med; 2000 Jan; 135(1):57-65. PubMed ID: 10638695
[TBL] [Abstract][Full Text] [Related]
8. Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile.
Nasrallah GK; Salem R; Da'as S; Al-Jamal OLA; Scott M; Mustafa I
Neurotoxicol Teratol; 2019; 72():29-38. PubMed ID: 30710618
[TBL] [Abstract][Full Text] [Related]
9. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
11. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
12. Renal clearable nanochelators for iron overload therapy.
Kang H; Han M; Xue J; Baek Y; Chang J; Hu S; Nam H; Jo MJ; El Fakhri G; Hutchens MP; Choi HS; Kim J
Nat Commun; 2019 Nov; 10(1):5134. PubMed ID: 31723130
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
14. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
Liu Z; Lin TM; Purro M; Xiong MP
ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
[TBL] [Abstract][Full Text] [Related]
15. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
Hallaway PE; Eaton JW; Panter SS; Hedlund BE
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10108-12. PubMed ID: 2481311
[TBL] [Abstract][Full Text] [Related]
16. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
Liu Z; Qiao J; Nagy T; Xiong MP
J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients.
Stivelman J; Schulman G; Fosburg M; Lazarus JM; Hakim RM
Kidney Int; 1989 Dec; 36(6):1125-32. PubMed ID: 2601259
[TBL] [Abstract][Full Text] [Related]
19. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
